Research Analysts Set Expectations for AURA FY2024 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for Aura Biosciences in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($1.67) for the year, up from their prior forecast of ($1.68). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.44) EPS, FY2025 earnings at ($1.93) EPS and FY2026 earnings at ($2.21) EPS.

Several other brokerages have also issued reports on AURA. BTIG Research raised their target price on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, Scotiabank upped their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $23.00.

Aura Biosciences Trading Down 3.5 %

Shares of AURA opened at $9.97 on Friday. The stock has a 50 day moving average of $9.75 and a 200 day moving average of $8.50. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The company has a market capitalization of $494.61 million, a price-to-earnings ratio of -5.81 and a beta of 0.33.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02.

Insider Activity

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Julie B. Feder sold 25,131 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the transaction, the chief financial officer now owns 134,276 shares in the company, valued at approximately $1,615,340.28. This represents a 15.77 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,259 shares of company stock valued at $780,699. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. bought a new position in shares of Aura Biosciences during the second quarter valued at approximately $119,000. American International Group Inc. lifted its position in shares of Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares during the period. Virtu Financial LLC purchased a new position in shares of Aura Biosciences during the first quarter valued at about $144,000. SG Americas Securities LLC purchased a new stake in Aura Biosciences in the third quarter worth about $169,000. Finally, Rhumbline Advisers boosted its position in Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.